{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:55:55Z","timestamp":1792068955411,"version":"4.4.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Unintentional doping violations have been reported after secondary skin exposure, including partner contact or contact sports. Methyltestosterone (MT), an anabolic androgenic steroid on the World Anti\u2010Doping Agency Prohibited List, is readily available in Japan as an over\u2010the\u2010counter topical hair\u2010growth preparation and as oral tablets. This study evaluated whether transdermal absorption of MT can be distinguished from oral administration using human urine and dried blood spot (DBS) analyses. Ten men received MT once daily for five consecutive days (five oral, five transdermal). The urinary tetrahydro\u2010metabolites 17\u03b1\u2010methyl\u20105\u03b1\u2010androstane\u20103\u03b1,17\u03b2\u2010diol (5\u03b1\u2010THMT) and 17\u03b1\u2010methyl\u20105\u03b2\u2010androstane\u20103\u03b1,17\u03b2\u2010diol (5\u03b2\u2010THMT) were detectable within hours after administration for both routes. Following transdermal administration, 5\u03b1\u2010THMT remained detectable up to 97\u2009h after the final administration, whereas, after oral administration, 5\u03b2\u2010THMT persisted longer, up to 265\u2009h. Transdermal application produced a marked increase in 5\u03b1\u2010THMT, consistent with high 5\u03b1\u2010reductase activity in skin, yielding a significantly higher 5\u03b1\u2010THMT\/5\u03b2\u2010THMT ratio than after oral administration. Nonetheless, individuals with inherently high 5\u03b1\u2010reductase activity may exhibit elevated ratios even after oral dosing, warranting careful interpretation. In DBS after oral dosing, parent MT was generally detectable up to 24\u2009h, providing a shorter detection window than urinary tetrahydro\u2010metabolites. Overall, combining urine (tetrahydro\u2010metabolites) and DBS (parent MT) analyses enables effective detection of MT use and supports differentiation of administration routes.<\/jats:p>","DOI":"10.1002\/dta.3962","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:47:03Z","timestamp":1761223623000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Distinguishing Between Oral and Transdermal Administration Routes of Methyltestosterone Through Human Urine and Dried Blood Spot Analyses for Doping Control Purposes"],"prefix":"10.1002","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-4121","authenticated-orcid":false,"given":"Masato","family":"Okano","sequence":"first","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3927-6576","authenticated-orcid":false,"given":"Asami","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ota","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"World Anti\u2010Doping Agency \u201cWorld Anti\u2010Doping Code. International Standard. Prohibited list 2025 Montreal 2024 \u201d accessed June 4 2025 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2024\u201009\/2025list_en_final_clean_12_september_2024.pdf."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.022210"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2951"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fspor.2024.1480373"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3355"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2023.106444"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022\u20104731(86)90359\u20106"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrine1927.60.11_1281"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00156735"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000072930"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20140220"},{"key":"e_1_2_7_13_1","first-page":"133","volume-title":"Recent Advances in Doping Analysis","author":"Geyer H.","year":"2007"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2341"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20101481\u20108683"},{"key":"e_1_2_7_16_1","unstructured":"World Rugby \u201cIRB Annual Review 2011 Dublin Ireland \u201d (2011) accessed March 25 2025 http:\/\/resources.world.rugby\/worldrugby\/document\/2014\/11\/16\/34300051\u201068e7\u201043e6\u201088d4\u2010fe3b9f59ad19\/IRB\u2010YearinReview2011\u2010English.pdf."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/42.7.1001"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3381"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3914"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3846"},{"key":"e_1_2_7_21_1","unstructured":"World Anti\u2010Doping Agency \u201cThe World Anti\u2010Doping Code. International Standard for Laboratories (ISL) 2021 Montreal 2021 \u201d accessed March 24 2025 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/isl_2021.pdf."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3367"},{"key":"e_1_2_7_23_1","unstructured":"World Anti\u2010Doping Agency \u201cMeasurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) Markers of the Urinary Steroid Profile. WADA Technical Document\u2013TD2021EAAS Montreal 2021 \u201d accessed May 2 2025 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2022\u201001\/td2021eaas_final_eng_v_2.0.pdf."},{"key":"e_1_2_7_24_1","unstructured":"World Anti\u2010Doping Agency \u201cWorld Anti\u2010Doping Agency. Minimum Criteria for Chromatographic\u2010Mass Spectrometric Confirmation of the Identify if Analytes for Doping Control Purposes. WADA Technical Document\u2013TD2023IDCR Montreal \u201d (2023) accessed December 4 2023 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2023\u201002\/td2023idcrv1.1_eng_final.pdf."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3589"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552\u20104604.1973.tb00075.x"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.3962","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:31:19Z","timestamp":1768307479000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/dta.3962"],"URL":"https:\/\/doi.org\/10.1002\/dta.3962","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"2025-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}